BARCELONA (Reuters) - A new heart failure drug from Novartis cut the risk of both cardiovascular death and hospitalization by a fifth in a keenly awaited study, boosting hopes for a product that is seen as a multibillion-dollar seller.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment